BioLineRx Ltd. (BLRX)
- Previous Close
0.5753 - Open
0.5614 - Bid 0.5843 x 100
- Ask 0.6343 x 100
- Day's Range
0.5528 - 0.6216 - 52 Week Range
0.5500 - 2.5300 - Volume
581,327 - Avg. Volume
424,730 - Market Cap (intraday)
48.891M - Beta (5Y Monthly) 0.93
- PE Ratio (TTM)
-- - EPS (TTM)
-0.9000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
13.75
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
www.biolinerx.comRecent News: BLRX
Performance Overview: BLRX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BLRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BLRX
Valuation Measures
Market Cap
52.60M
Enterprise Value
21.20M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.18
Price/Book (mrq)
3.70
Enterprise Value/Revenue
4.42
Enterprise Value/EBITDA
-0.37
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-38.30%
Return on Equity (ttm)
-189.23%
Revenue (ttm)
4.8M
Net Income Avi to Common (ttm)
-60.61M
Diluted EPS (ttm)
-0.9000
Balance Sheet and Cash Flow
Total Cash (mrq)
42.99M
Total Debt/Equity (mrq)
87.66%
Levered Free Cash Flow (ttm)
-9.6M